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S-1, a novel oral fluoropyrimidine, is an effective therapeutic agent for gastric cancer. Herein, we report a case with 
locally advanced gastric cancer that achieved a curative resection after S-1 monotherapy as neoadjuvant treatment. A 
68-year-old man was diagnosed with gastric cancer and massive lymphadenopathy involving the perigastric, celiac axis 
and splenic hilum. His clinical stage was cT3N2H0P0M0. Considering his relatively poor performance (ECOG 2, severe 
w e i g h t  l o s s )  a n d  a d v a n c e d  a g e ,  w e  s t a r t e d  t h e  p a t i e n t  o n  S - 1  m o notherapy  at  a  dose  of  35  mg/m
2 b i d  f o r  4  
consecutive weeks followed by a 2-week rest. Follow-up study after 4 treatment cycles revealed disappearance of the 
lymphadenopathy of the perigastric and celiac axis with diminished extension of the stomach mass. The patient had a 
partial  response  (PR)  with  a  72%  tumor  reduction,  according  to  the  Response  Evaluation  Criteria  in  Solid  Tumors 
(RECIST).  His  performance  status  was  improved  to  an  ECOG  1  and  he  gained  7  kg.  A  curative  (R0)  resection  was 
achieved  with  a  radical  total  gastrectomy  and  D2  dissection.  The  pathological  stage  was  pT3N2M0,  stage  IIIB.  In 
conclusion,  S-1  neoadjuvant  chemotherapy  aided  in  the  treatment  of  gastric  cancer  in  this  patient. 
Key  Words  :  Gastric  cancer;  S-1;  Neoadjuvant  therapy
∙Received  :  October  11,  2006
∙Accepted  :  December  28,  2006
∙Correspondence to : Hei-Cheul  Jeung,  M.D.,  Ph.D.  Cancer  Metastasis  Research  Center,  Yonsei  Cancer  Center,  Yonsei  University  College  of  Medicine, 
134,  Shinchon-Dong,  Seodaemoon-gu,  CPO  Box  #  8044,  Seoul  120-752,  Korea    Tel  :  82-2-2228-8051,  Fax  :  82-2-362-5592
E-mail  :  jeungchc1123@yumc.yonsei.ac.kr
*This work was supported by a grant from Korea Science and Engineering Foundation (KOSEF) through the Cancer Metastasis Research Center at Yonsei 
University,  College  of  Medicine.
INTRODUCTION
Surgery is the main treatment strategy for gastric cancer; only 
R0  resection  anticipates  a  potential  cure.  The  prognosis  of 
initially  unresectable  gastric  cancer  is  poor;  approximately  50% 
of patients have recurrent disease after a curative resection. This 
suggests  that  micrometastases  are  already  present,  in  many 
cases,  at  the  time  of  surgery
1).  Neoadjuvant  chemotherapy  has 
been attempted  for  the treatment  of  gastric  cancers in patients 
with  advanced  T  and  N  stage  disease  for  the  purpose  of 
downstaging,  improving  resectability  and  survival
2).  Several 
neoadjuvant  trials have  been reported  to  provide  such benefits. 
Several  regimens  containing  cisplatin,  anthracyclines  and 
methotrexate  are  the  main  chemotherapeutic  options.  These 
regimens  have  demonstrated  a  response  rate  (RR)  of  34～69% 
and a resectability of 36～60%, with a median survival of 16～28 
months for initially unresectable or stage III-IV cases. However, in 
19～33%  of  patients,  the  associated  adverse  effects  of  up  to 
grade 3-4 have impeded the use of these agents
3-6). Therefore, 
the selection of patients with a good performance status is the 
first  consideration  for  effective  neoadjuvant  chemotherapy.
S-1  is  a fourth-generation  oral  fluoropyrimidine  based on  the 
combination  of  tegafur  with  two  biochemical  modulators, 
5-chloro-2,4-dihydroxypyridine  (CDHP)  and  potassium  oxonate 
(Oxo).  S-1  mimics  the  protracted  continuous  infusion  of 
5-fluorouracil  (5-FU)  with  enhanced  efficacy  and  safety
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Figure  1.  Initial  endoscopic  and  radiological  findings,  (A)  Endoscopy 
demonstrating  a  diffuse-infiltrative  lesion  at  the  great  curvature  of  the 
u p p e r  b o d y  o f  t h e  s t o m a c h .  ( B )  M i c r o s c o p i c  f i n d i n g s  o f  a d e n o c a rcinoma 
with  poor  lumen  formation  (H&E,  ×400).  (C-E)  Abdominal-  pelvic 
computed  tomography  (CT)  showing  a  malignant  mass  in  the  stomach 
(arrow) (D), and multiple metastatic lymph nodes in the perigastric, upper 
retroperitoneum  close  to  celiac  axis  (long  arrow)  (E),  and  splenic  hilum 
(thick  arrow)  (C).
earlier and two more current, phase II trials with monotherapy for 
advanced gastric cancer, in Japan, achieved a remarkable RR of 
45% and 54% respectively. These results are consistent with the 
commonly  used  combination  regimens  containing  cisplatin  or 
anthracyclines
8, 9).  S-1  is  also  known  to  have  less  toxicity  than 
other  active  agents  in  the  treatment  of  gastric  cancer. 
Nevertheless, there are only a few reports evaluating its efficacy 
for  neoadjuvant  treatment.  In  retrospective  analyses,  S-1  in 
combination with cisplatin achieved a RR of 44% and 79% and 
a  downstaging  rate  of  47%  and  85%,  respectively
10, 11). 
Furthermore,  S-1  monotherapy  as  neoadjuvant  treatment  has 
recentlybeen  reported  to  induce  a  pathologically  complete 
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Figure 2. Follow-up endoscopic and radiological findings after 4 cycles of S-1 treatment. (A) Endoscopy demonstrating a reduced stomach mass. 
(B-D)  Abdominal-pelvic  CT  showing  disappearance  of  the  lymph  nod e  e n l a r g e m e n t  a r o u n d  t h e  p e r i g a s t r i c  a r e a  a n d  c e l i a c  a x i s  ( D ) ,  a n d  a l s o  
d i m i n i s h e d  s p l e n i c  h i l a r  l y m p h  n o d e s  ( l o n g  a r r o w )  ( B )  a l o n g  w i th  a  decreased  stomach  mass  (C).
response (CR)
12, 13) and curative resection. Based on these data, 
we  report  herein  S-1  monotherapy  as  neoadjuvant  treatment  in 
a  patient  with  locally  advanced  gastric  cancer  and  poor 
performance  status  who  achieved  a    curative  resection. 
CASE REPORT
A 68-year-old man with epigastric pain, anorexia and general 
weakness for 6 months was admitted to our hospital. He lost 9 
kg in the last 6 months (12% loss). There was neither history of 
pre-existing  chronic  disease  nor  a  family  history  of  gastric 
cancer.  His  performance  status  was  2  according  to  the  criteria 
of  the  Eastern  Cooperative  Oncology  Group  (ECOG).
Endoscopic  examination  demonstrated  a  diffuse-infiltrative 
l e s i o n  a l o n g  t h e  g r e a t  c u r v a t u r e  o f  t h e  u p p e r  b o d y  o f  t h e  
stomach;  the  biopsy  confirmed  a  moderately  differentiated 
adenocarcinoma  (Figure  1A,  1B).  Abdominal-pelvic  computed 
tomography  (CT)  showed  a  gastric  cancer  with  massive  lymph 
node enlargement in the perigastric area, upper retroperitoneum 
close to the celiac axis and the splenic hilum with no evidence 
of  distant  or  peritoneal  metastases  (Figure  1C,  1D,  1E).  The 
clinical stage of the patient was cT3N2H0P0M0 according to the 
staging  system  of  the  Japanese  Gastric  Cancer  Association 
(JGCA).
Neoadjuvant  chemotherapy  was  considered  for  this  patient 
because of the advanced nodal involvement. However, significant 
weight  loss,  advanced  age  and  a  relatively  poor  general 
condition  prevented  full-dose  administration  of  a  multi-drug 
systemic  chemotherapy  regimen.  Alternately,  we  planned  S-1 
monotherapy  at  a  dose  of  35  mg/m
2  twice  a  day  for  4 
consecutive  weeks  followed  by  a  2-week  resting  period.
Follow-up endoscopy after 4 cycles showed a decrease in the 
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Figure  3.  Microscopic  findings  of  the  resected  stomach  showing 
transmural involvement of the tumor and a minor pathological response; 
more  than  50%  of  the  tumor  bed  is  composed  of  tumor  cells, 
according  to  Becker's  criteria  (H&E,  ×400).
extent  of  infiltrative  lesions  of  the  stomach  (Figure  2A).  The  CT 
scan  demonstrated  the  disappearance  of  lymph  node 
enlargement  around  the  perigastric  area,  celiac  axis  and  also  a 
decrease in the size of the splenic hilar lymph nodes along with 
a reduction in the stomach mass (Figure 2B, 2C, 2D). According 
to the RECIST criteria, a PR with a 72% decrease of the target 
lesions (sum of target lesion, 90 mm to 26 mm) was achieved. 
During the 4 cycles of treatment, there was no treatment delay 
or dose reduction due to adverse events. The patient had grade 
1 fatigue and nausea and grade 2 skin rashes without any grade 
3-4 toxicity. The performance status improved to ECOG 1 after 
the  administration  of  S-1  and  the  patient  gained  7  kg  of  body 
weight.  The  diagnostic  laparoscopy  showed  a  serosa-  involving 
lesion  on  the  upper  body  of  the  stomach  extending  from  the 
anterior  to  the  posterior  wall  with  severe  adhesions  and 
surrounding  tissues. 
A  radical  total  gastrectomy  with  D2  lymph  node  dissection 
and  combined  splenectomy  were  performed.  Macroscopically, 
the  excised  specimen  showed  a  diffuse  infiltrative  lesion  with 
serosal  surface  exposure  (se)  measuring  180×130  mm. 
Microscopically,  there  was  transmural  involvement  of  the  tumor 
(Figure 3). Metastatic adenocarcinoma in 12 out of 65 resected 
lymph  nodes  was  noted.  An  adequate  resection  margin  was 
obtained  on  both  ends  and  there  was  no  microscopic 
involvement  at  the  margins  identified.  According  to  Becker's 
criteria,  more  than  50%  of  the  tumor  bed  was  composed  of 
tumor cells; therefore, the pathological response was defined as 
minor
14).  The  final  pathological  stage  was  pT3N2M0  (H0P0), 
Stage IIIB, according to both the JGCA and the American Joint 
Committee  on  Cancer  (AJCC)  systems.  The  postoperative  CT 
scan showed no evidence of residual disease. After an additional 
3  cycles  of  S-1  monotherapy  were  administered  as  adjuvant 
chemotherapy, the patient is without any evidence of recurrence 
after  6  months  of  follow-up. 
DISCUSSION
Neoadjuvant  chemotherapy  for  locally  advanced  gastric 
cancer  has  several  advantages.  Early  initiation  of  systemic 
therapy  may  result  in  disease  downstaging,  eliminate  microme-
tastases  and  enable  a  curative  resection.  Furthermore, 
neoadjuvant  chemotherapy  provides  prognostic  information  due 
to  the  in  vivo  chemosensitivity  testing.  However,  there  are  also 
potential  risks  involved.  By  delaying  definitive  local  therapy, 
treatment-resistant  clones  can  emerge  during  therapy.  In 
addition,  considerable  tumor  shrinkage  is  required  in  a  short 
period  for  the  chemotherapeutic  regimen  to  obtain  effective 
downstaging with the neoadjuvant treatment. However, regimens 
w i t h  a  h i g h  t u m o r  r e s p o n s e  a r e  u s u a l l y  a s s o c i a t e d  w i t h  
substantial  toxicity.  Therefore,  neoadjuvant  therapy  may  not  be 
feasible  in  some  circumstances  such  as  in  patients  with  an 
unfavorable  performance  status  or  advance  age.  In  the  clinical 
trials  using  cisplatin  or  anthracycline-based  regimens,  although 
downstaging  was  attained,  only  20～54%  of  the  patients 
completed  the  planned  treatment.  As  many  as  one-third  of  the 
patients  experienced  grade  3-4  adverse  events
3-6).
Therefore,  novel  chemotherapeutic  agents  such  as  taxanes, 
irinotecan  and  oral  fluoropyrimidines  might  be  candidates  for 
future  neoadjuvant  trials  with  effects  on  tumor  shrinkage 
comparable  to  and  more  favorable  toxicity  profiles  than 
traditional  agents.
Among  the  above  cited  agents,  S-1  might  be  a  useful 
treatment option because of the results of several phase II trials 
on advanced gastric cancer. There are a few reports on S-1 in 
the neoadjuvant setting. Two Japanese retrospective analyses of 
S-1,  in  combination  with  cisplatin  as  neoadjuvant  treatment  in 
stage  III-IV  disease,  achieved  a  RR  of  44%  and  79%  and  a 
downstaging rate of 47% and 85%, respectively. However, these 
hi gh responses are mainl y due to a high PR not a pathologi cal 
CR  possibly  implicating  a  survival  benefit
10, 11).  Recently, 
p r e o p e r a t i v e  a d m i n i s t r a t i o n  o f  S - 1  a l o n e  h a s  b e e n  s h o w n  t o  
induce favorable responses in patients in poor clinical condition. 
The  total  disappearance  of  peritoneal  dissemination  was 
observed  with  S-1  and  cisplatin,  and  there  was  a  pathological 
CR in a 78-year old patient who was treated with S-1 alone
12). 
Our  selection  of  S-1  in  the  present  case  was  based  on  these 
findings. Our patient was not a candidate for full-dose multi-drug 
systemic chemotherapy due to his poor health status. Although 
downstaging  was  not  observed  in  our  case,  probably  due  to  a 
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the  massive  lymphadenopathy  around  the  celiac  axis.  This  is 
consistent with other phase II studies on S-1 monotherapy that 
reported a higher efficacy for the abdominal lymph nodes (75%) 
compared to the primary gastric mass (28%) or visceral organs 
(30%)
9).
Another  aspect  of  neoadjuvant  chemotherapy  to  consider  is 
safety, which in turn is associated with treatment compliance. In 
this respect, S-1 has an advantage with favorable toxicity profiles 
compared  to  other  agents.  Neutropenia  and  anemia  were  the 
m a i n  a d v e r s e  e v e n t s  r e p o r t e d  i n  A s i a n  p a t i e n t s
9, 15)  and  the 
neoadjuvant combination with cisplatin showed only 7% of cases 
w i t h  g r a d e  3 - 4  a d v e r s e  e v e n t s
10, 11).  Our  patient  finished  the 
treatment  without  significant  toxicity  or  dose  reduction. 
Moreover,  the  patient  reported  a  sense  of  well  being,  had  an 
improved  appetite  and  gained  weight.  Therefore,  S-1 
monotherapy  was  safe  and  effective  treatment  for  this  patient 
and might be considered in the future as neoadjuvant treatment 
for  gastric  cancer.  In  conclusion,  the  results  of  this  case  study 
suggest that S-1 might be a safe and effective treatment option 
for  neoadjuvant  chemotherapy  in  locally  advanced  gastric 
cancer,  especially  when  accompanied  byperigastric  lymphade-
nopathy  and  a  poor  general  health  status  in  patients  of 
advanced age. The role of S-1 in the neoadjuvant setting for the 
treatment of gastric cancer remains to be established by clinical 
trials.
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